Zevra Therapeutics Inc. (ZVRA)
Zevra Therapeutics Statistics
Share Statistics
Zevra Therapeutics has 54.12M shares outstanding. The number of shares has increased by 29.3% in one year.
Shares Outstanding | 54.12M |
Shares Change (YoY) | 29.3% |
Shares Change (QoQ) | 1.39% |
Owned by Institutions (%) | 70.89% |
Shares Floating | 53.53M |
Failed to Deliver (FTD) Shares | 14.85K |
FTD / Avg. Volume | 3.44% |
Short Selling Information
The latest short interest is 5.47M, so 10.25% of the outstanding shares have been sold short.
Short Interest | 5.47M |
Short % of Shares Out | 10.25% |
Short % of Float | 10.31% |
Short Ratio (days to cover) | 10.4 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -196.75. Zevra Therapeutics's PEG ratio is undefined.
PE Ratio | undefined |
Forward PE | -196.75 |
PS Ratio | 16.34 |
Forward PS | 1.1 |
PB Ratio | 9.72 |
P/FCF Ratio | undefined |
PEG Ratio | undefined |
Enterprise Valuation
Zevra Therapeutics Inc. has an Enterprise Value (EV) of 232.93M.
EV / Earnings | -2.21 |
EV / Sales | 9.86 |
EV / EBITDA | -3.05 |
EV / EBIT | -2.68 |
EV / FCF | -3.34 |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of undefined.
Current Ratio | 2.53 |
Quick Ratio | 2.47 |
Debt / Equity | undefined |
Total Debt / Capitalization | 60.32 |
Cash Flow / Debt | -1.16 |
Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is -2.66% and return on capital (ROIC) is -101.88%.
Return on Equity (ROE) | -2.66% |
Return on Assets (ROA) | -0.59% |
Return on Capital (ROIC) | -101.88% |
Revenue Per Employee | $400,203.39 |
Profits Per Employee | $-1,788,322.03 |
Employee Count | 59 |
Asset Turnover | 0.13 |
Inventory Turnover | 3.76 |
Taxes
Income Tax | 15.37M |
Effective Tax Rate | -0.17 |
Stock Price Statistics
The stock price has increased by 45.35% in the last 52 weeks. The beta is 1.98, so Zevra Therapeutics's price volatility has been higher than the market average.
Beta | 1.98 |
52-Week Price Change | 45.35% |
50-Day Moving Average | 7.89 |
200-Day Moving Average | 7.56 |
Relative Strength Index (RSI) | 40.3 |
Average Volume (20 Days) | 431.39K |
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of 23.61M and earned -105.51M in profits. Earnings per share was -2.28.
Revenue | 23.61M |
Gross Profit | 16.2M |
Operating Income | -87M |
Net Income | -105.51M |
EBITDA | -76.4M |
EBIT | -87M |
Earnings Per Share (EPS) | -2.28 |
Balance Sheet
The company has 33.78M in cash and 60.3M in debt, giving a net cash position of -26.51M.
Cash & Cash Equivalents | 33.78M |
Total Debt | 60.3M |
Net Cash | -26.51M |
Retained Earnings | -505.29M |
Total Assets | 178.13M |
Working Capital | 51.96M |
Cash Flow
In the last 12 months, operating cash flow was -69.67M and capital expenditures 0, giving a free cash flow of -69.67M.
Operating Cash Flow | -69.67M |
Capital Expenditures | 0 |
Free Cash Flow | -69.67M |
FCF Per Share | -1.51 |
Margins
Gross margin is 68.59%, with operating and profit margins of -368.47% and -446.85%.
Gross Margin | 68.59% |
Operating Margin | -368.47% |
Pretax Margin | -381.76% |
Profit Margin | -446.85% |
EBITDA Margin | -323.56% |
EBIT Margin | -368.47% |
FCF Margin | -295.04% |
Dividends & Yields
ZVRA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -30.4% |
FCF Yield | -17.15% |
Analyst Forecast
The average price target for ZVRA is $21.5, which is 186.7% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $21.5 |
Price Target Difference | 186.7% |
Analyst Consensus | Strong Buy |
Analyst Count | 8 |
Stock Splits
The last stock split was on Dec 28, 2020. It was a backward split with a ratio of 1:16.
Last Split Date | Dec 28, 2020 |
Split Type | backward |
Split Ratio | 1:16 |
Scores
Altman Z-Score | -3.16 |
Piotroski F-Score | 3 |